Ocular Therapeutix reports strong Q1 2026 with positive Phase 3 trial results for AXPAXLI in wet AMD

Ocular Therapeutix announced positive Phase 3 SOL-1 trial results for AXPAXLI, showing superior and durable outcomes in treating wet age-related macular degeneration (AMD). The company is advancing regulatory submission plans with the FDA and has initiated enrollment in a long-term extension trial (SOL-X). Financially, Ocular holds $666.7 million in cash, supporting operations into 2028, while continuing progress on additional trials including SOL-R and HELIOS-3. An Investor Day is scheduled for June 17, 2026, to provide further updates on clinical and commercial developments.